...
首页> 外文期刊>eLife journal >More effective drugs lead to harder selective sweeps in the evolution of drug resistance in HIV-1
【24h】

More effective drugs lead to harder selective sweeps in the evolution of drug resistance in HIV-1

机译:更有效的药物导致HIV-1耐药性演变过程中的选择性筛选更加困难

获取原文
           

摘要

In the early days of HIV therapy, the strains of the virus that infected patients frequently evolved drug resistance and the therapies would often eventually fail. These treatments generally involved using a single anti-viral drug. Nowadays, better therapies involving combinations of several anti-viral drugs are available and drug resistance in HIV is a much rarer occurrence. This means that now a particular therapy may be an effective treatment for an HIV-infected individual over much longer periods of time. A theory of population genetics predicts that when it is easy for a population to acquire a beneficial genetic mutation – like one that provides drug resistance – multiple versions of that mutation may spread in the population at the same time. This is called a soft selective sweep. However, when beneficial mutations occur only rarely, it is expected that only one version of that mutation will take over in a population, which is known as a hard selective sweep. Here, Feder et al. test this theory using data from 6717 patients with HIV who were treated between 1989 and 2013 using a variety of different drug therapies. The experiments aimed to find out whether the transition from the older drug therapies –where the virus frequently acquired resistance – to the newer, more effective drugs was associated with a transition from soft to hard sweeps. Feder et al. find that HIV more often evolved drug resistance via soft sweeps in patients treated with the less effective drug combinations (like those given in the early days of HIV treatment), while hard sweeps were more common with the more effective drug combinations. This suggests that good drug combinations may allow fewer drug resistance mutations to occur in the HIV population within a patient. This may be because there are fewer virus particles in these patients, or because the specific combinations of mutations that provide resistance occur less often. Feder et al.’s findings are a step towards understanding why modern HIV treatments work so well, which will ultimately help us find better treatments for other infectious diseases.
机译:在HIV治疗的早期,感染患者的病毒株经常会产生耐药性,并且治疗最终往往会失败。这些治疗通常涉及使用单一抗病毒药物。如今,可获得更好的疗法,涉及几种抗病毒药物的组合,而艾滋病毒中的耐药性则很少见。这意味着,现在特定的疗法可能会在更长的时间内成为感染HIV的个体的有效疗法。人群遗传学理论预测,当一个人群很容易获得有益的基因突变(如提供耐药性的突变)时,该突变的多个版本可能会同时在人群中传播。这称为软选择性扫描。但是,当有益突变很少发生时,可以预期该突变中只有一个版本会在种群中接管,这称为硬选择扫描。在这里,Feder等人。使用1989年至2013年之间使用各种不同药物疗法治疗的6717例HIV患者的数据对这一理论进行检验。这些实验旨在发现从旧的药物疗法(病毒经常获得抗药性)到新的,更有效的药物的过渡是否与从轻扫到硬扫的过渡有关。费德等。研究发现,在使用效果较差的药物组合治疗的患者中,HIV更容易通过软扫除产生耐药性(如在HIV治疗初期所给予的治疗),而使用效果更强的药物组合进行硬扫除更常见。这表明良好的药物组合可能会使患者的HIV人群中发生较少的耐药性突变。这可能是因为这些患者中的病毒颗粒较少,或者是因为提供抗性的突变的特定组合较少出现。费德(Feder)等人的发现是朝着理解现代HIV治疗为何如此有效的方向迈出的一步,这最终将有助于我们找到其他传染病的更好治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号